Published in Gut on September 01, 2004
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 14.16
Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev (2007) 1.65
Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing. PLoS One (2011) 1.39
Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol (2007) 1.38
Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy. World J Gastroenterol (2007) 1.22
Sequence diversity of hepatitis C virus: implications for immune control and therapy. World J Gastroenterol (2007) 1.21
Evidence of recombination in intrapatient populations of hepatitis C virus. PLoS One (2008) 1.16
Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis: Meta-analysis of IL28B. Hepat Mon (2011) 1.06
Genetic variation of hepatitis C virus in a cohort of injection heroin users in Wuhan, China. Virus Res (2008) 1.02
Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview. World J Gastroenterol (2014) 0.94
Coevolution of the hepatitis C virus polyprotein sites in patients on combined pegylated interferon and ribavirin therapy. J Virol (2011) 0.92
Regulation of PKR by HCV IRES RNA: importance of domain II and NS5A. J Mol Biol (2010) 0.92
Predicting the probable outcome of treatment in HCV patients. Therap Adv Gastroenterol (2009) 0.92
The natural history of early hepatitis C virus evolution; lessons from a global outbreak in human immunodeficiency virus-1-infected individuals. J Gen Virol (2011) 0.92
Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C. J Gastroenterol (2009) 0.91
Baseline prediction of combination therapy outcome in hepatitis C virus 1b infected patients by discriminant analysis using viral and host factors. PLoS One (2010) 0.90
Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses. J Virol (2008) 0.88
Genetic diversity of NS5A protein from hepatitis C virus genotype 3a and its relationship to therapy response. BMC Infect Dis (2010) 0.86
Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy. World J Gastroenterol (2007) 0.84
A set of reference sequences for the hepatitis C genotypes 4d, 4f, and 4k covering the full open reading frame. J Med Virol (2008) 0.83
Sequencing of the Hepatitis C Virus: A Systematic Review. PLoS One (2013) 0.83
Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy. PLoS One (2012) 0.82
The hepatitis C virus NS5A protein and response to interferon alpha: mutational analyses in patients with chronic HCV genotype 3a infection from India. Med Microbiol Immunol (2006) 0.81
Genetic variability of hepatitis C virus before and after combined therapy of interferon plus ribavirin. PLoS One (2008) 0.81
Induction of IL-6 and CCL5 (RANTES) in human respiratory epithelial (A549) cells by clinical isolates of respiratory syncytial virus is strain specific. Virol J (2012) 0.80
Evolution of interferon-based therapy for chronic hepatitis C. Hepat Res Treat (2010) 0.79
The role of HCV proteins on treatment outcomes. Virol J (2015) 0.78
Predictors of virological response to a combination therapy with pegylated interferon plus ribavirin including virus and host factors. Hepat Res Treat (2010) 0.78
Analysis of HCV quasispecies dynamic under selective pressure of combined therapy. BMC Infect Dis (2013) 0.77
Prediction of hepatitis C virus interferon/ribavirin therapy outcome based on viral nucleotide attributes using machine learning algorithms. BMC Res Notes (2014) 0.77
The Association of Substitutions in the Hepatitis C Virus Subtype 1b Core Gene and IL28B Polymorphisms With the Response to Peg-IFNα-2a/RBV Combination Therapy in Azerbaijani Patients. Hepat Mon (2016) 0.77
Relevance of baseline viral genetic heterogeneity and host factors for treatment outcome prediction in hepatitis C virus 1b-infected patients. PLoS One (2013) 0.76
Quantitation of substitutions at amino acid 70 in hepatitis C virus genotype 1b. Virol J (2014) 0.76
Amino Acid Polymorphisms Within the Entire HCV NS5A Region in Estonian Chronic HCV 1b Patients With Different Treatment Response. Hepat Mon (2013) 0.75
Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy. Virol J (2015) 0.75
Effect of Hepatitis C Virus Genotype 1b Core and NS5A Mutations on Response to Peginterferon Plus Ribavirin Combination Therapy. Int J Mol Sci (2015) 0.75
A novel approach to identify candidate prognostic factors for hepatitis C treatment response integrating clinical and viral genetic data. Evol Bioinform Online (2015) 0.75
Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus. Nat Genet (2017) 0.75
CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res (1994) 392.47
A simple method for displaying the hydropathic character of a protein. J Mol Biol (1982) 150.65
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med (1996) 4.61
Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol (1998) 4.52
Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest (1995) 3.19
Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology (1995) 2.54
Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology (1996) 2.22
Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa. Hepatology (1997) 1.72
Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. Hepatology (1997) 1.54
Management strategies using pharmacogenomics in patients with severe HCV-1b infection: a decision analysis. Hepatology (2002) 1.47
Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology (2003) 1.39
Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b. J Med Virol (1997) 1.37
Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication. Hepatology (1999) 1.35
Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy. J Virol (2000) 1.32
Why is the interferon sensitivity-determining region (ISDR) system useful in Japan? J Hepatol (1999) 1.31
Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. J Gen Virol (1998) 1.27
Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment. Hepatology (2000) 1.23
Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients. J Hepatol (1997) 1.15
Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response. Gastroenterology (1999) 1.12
Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. Gastroenterology (1997) 1.10
Number and position of mutations in the interferon (IFN) sensitivity-determining region of the gene for nonstructural protein 5A correlate with IFN efficacy in hepatitis C virus genotype 1b infection. J Infect Dis (2001) 1.06
Two PKR inhibitor HCV proteins correlate with early but not sustained response to interferon. Gastroenterology (2000) 1.05
Mutations in the NS5A region do not predict interferon-responsiveness in american patients infected with genotype 1b hepatitis C virus. J Med Virol (1999) 1.04
Statistical analysis of combined substitutions in nonstructural 5A region of hepatitis C virus and interferon response. J Med Virol (2001) 1.04
The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus. J Infect Dis (1998) 1.03
The non-structural 5A protein of hepatitis C virus. J Viral Hepat (1999) 1.02
Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection. Dig Dis Sci (2002) 0.99
The interferon sensitivity determining region: all hepatitis C virus isolates are not the same. Hepatology (1997) 0.99
Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analyses. J Virol (2002) 0.92
Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C. J Med Virol (2001) 0.89
Variations within hepatitis C virus E2 protein and response to interferon treatment. Virus Res (2001) 0.89
Mutations in NS5A region of hepatitis C virus genome correlate with presence of NS5A antibodies and response to interferon therapy for most common European hepatitis C virus genotypes. Hepatology (1998) 0.86
Mutations in the nonstructural protein 5A gene and response to interferon therapy in young patients with chronic hepatitis C virus 1b infection. J Med Virol (1997) 0.85
The NS5a gene of hepatitis C virus in patients treated with interferon-alpha. J Med Virol (2000) 0.84
The "interferon sensitivity determining region" of hepatitis C virus is a stable sequence element. J Hepatol (1998) 0.83
Predictive factors in eradicating hepatitis C virus using a relatively small dose of interferon. J Gastroenterol Hepatol (1998) 0.81
Efficacy and changes of the nonstructural 5A GENE by prolonged interferon therapy for patients with hepatitis C virus genotype 1b and a high level of serum HCV-RNA. Intern Med (1999) 0.81
Mutations in the NS5A gene predict response to interferon therapy in Japanese patients with chronic hepatitis C and cirrhosis. Scand J Infect Dis (1999) 0.80
Interferon-alpha therapy in HCV hepatitis: HLA phenotype and cirrhosis are independent predictors of clinical outcome. Hum Immunol (1998) 0.80
NS5A mutations predict biochemical but not virological response to interferon-alpha treatment of sporadic hepatitis C virus infection in European patients. J Viral Hepat (2001) 0.80
Integrity of the NS5A (amino acid 2209 to 2248) region in hepatitis C virus 1b patients non-responsive to interferon therapy. Liver (2000) 0.79
Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nat Biotechnol (2001) 11.41
Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr 38,000 characteristic of presynaptic vesicles. Cell (1985) 6.06
TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch (2006) 5.86
Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA (1996) 4.31
TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch (2007) 3.89
Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology (2001) 3.26
Transport route for synaptobrevin via a novel pathway of insertion into the endoplasmic reticulum membrane. EMBO J (1995) 2.96
Clathrin-coated vesicles contain an ATP-dependent proton pump. Proc Natl Acad Sci U S A (1983) 2.84
IgE concentrations in children with atopic diseases. A clinical study. Int Arch Allergy Appl Immunol (1969) 2.84
Molecular characterization of the first Aichi viruses isolated in Europe and in South America. Arch Virol (2006) 2.60
Detection of a liver-membrane autoantibody in HBsAg-negative chronic active hepatitis. N Engl J Med (1976) 2.57
Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol (2004) 2.54
Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology (2005) 2.49
Isolation and characterization of rat liver amphisomes. Evidence for fusion of autophagosomes with both early and late endosomes. J Biol Chem (1998) 2.44
Transport and storage of vitamin A. Science (1990) 2.39
Liver-specific antigens of different species. II. Localization of a membrane antigen at cell surface of isolated hepatocytes. Clin Exp Immunol (1974) 2.36
Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors. Gastroenterology (1993) 2.29
Uptake and degradation of 125I-labelled asialo-fetuin by isolated rat hepatocytes. Biochim Biophys Acta (1977) 2.28
Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment. Virology (1995) 2.25
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat (2014) 2.23
Ultrastructural and immunocytochemical characterization of autophagic vacuoles in isolated hepatocytes: effects of vinblastine and asparagine on vacuole distributions. Exp Cell Res (1995) 2.03
Disposition of cyclosporine in several animal species and man. I. Structural elucidation of its metabolites. Drug Metab Dispos (1984) 2.01
Studies on the pathogenesis of experimental chronic active hepatitis in rabbits. I. Induction of the disease and protective effect of allogeneic liver specific proteins. Br J Exp Pathol (1974) 2.00
Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology (1998) 1.98
Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy. J Hepatol (2010) 1.95
Genome-wide scan for type 1 diabetic nephropathy in the Finnish population reveals suggestive linkage to a single locus on chromosome 3q. Kidney Int (2006) 1.91
Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res (2000) 1.90
Magnetic resonance cholangiopancreatography-guided unilateral endoscopic stent placement for Klatskin tumors. Gastrointest Endosc (2001) 1.90
Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat (2008) 1.85
Improved semiautomatic method for morphometry of angiogenesis and lymphangiogenesis in corneal flatmounts. Exp Eye Res (2008) 1.85
Analysis of integrated virological and epidemiological reports of norovirus outbreaks collected within the Foodborne Viruses in Europe network from 1 July 2001 to 30 June 2006. J Clin Microbiol (2008) 1.80
Complications of limb lengthening. A learning curve. Clin Orthop Relat Res (1994) 1.77
[Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection]. Z Gastroenterol (2010) 1.76
Molecular characterization of synaptophysin, a major calcium-binding protein of the synaptic vesicle membrane. EMBO J (1986) 1.73
LI-cadherin: a marker of gastric metaplasia and neoplasia. Gut (2001) 1.72
Pancreatic carcinoma. Lancet (1997) 1.72
Synaptophysin: a marker protein for neuroendocrine cells and neoplasms. Proc Natl Acad Sci U S A (1986) 1.70
Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat (2014) 1.68
Lysosomal enzyme trafficking between phagosomes, endosomes, and lysosomes in J774 macrophages. Enrichment of cathepsin H in early endosomes. J Biol Chem (1998) 1.67
Comprehensive microRNA expression profiling of the hematopoietic hierarchy. Proc Natl Acad Sci U S A (2010) 1.67
Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat (2014) 1.67
Immunoglobulin levels in healthy children. Acta Paediatr Scand (1967) 1.66
Comparative study of six rotary nickel-titanium systems and hand instrumentation for root canal preparation. Int Endod J (2005) 1.65
TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst (2012) 1.65
Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut (2004) 1.65
Controlled clinical laboratory comparison of two supplemented aerobic and anaerobic media used in automated blood culture systems to detect bloodstream infections. J Clin Microbiol (1998) 1.64
Role of stress in functional gastrointestinal disorders. Evidence for stress-induced alterations in gastrointestinal motility and sensitivity. Dig Dis (2001) 1.63
In vitro diagnosis of atopic allergy. I. A comparison between provocation tests and the radioallergosorbent test. Int Arch Allergy Appl Immunol (1971) 1.60
LM-Ag and LSP--two different target antigens involved in the immunopathogenesis of chronic active hepatitis? Clin Exp Immunol (1979) 1.59
Vitamin A metabolism: new perspectives on absorption, transport, and storage. Physiol Rev (1991) 1.59
Health-related quality of life in patients with pancreatic cancer. Digestion (2006) 1.57
Chloroquine reduces the number of asialo-glycoprotein receptors in the hepatocyte plasma membrane. Biochem Pharmacol (1979) 1.56
How to assess disease activity in patients with chronic urticaria? Allergy (2008) 1.55
Quantification of aqueous melanin granules in primary pigment dispersion syndrome. Am J Ophthalmol (1998) 1.55
[S3-Guidelines "Exocrine pancreatic cancer" 2007]. Z Gastroenterol (2007) 1.52
Synaptophysin expression in neuroendocrine neoplasms as determined by immunocytochemistry. Am J Pathol (1987) 1.51
The clinical significance of IgE. Prog Clin Immunol (1972) 1.51
Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. Leukemia (2010) 1.51
Pseudoexfoliation syndrome and aneurysms of the abdominal aorta. Lancet (2001) 1.50
The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model. Gut (2008) 1.49
Liver-cell-membrane autoantibody specific for inflammatory liver diseases. Br Med J (1977) 1.48
Antibodies to hepatitis C virus. Lancet (1989) 1.47
Uptake and degradation of formaldehyde-treated 125I-labelled human serum albumin in rat liver cells in vivo and in vitro. Biochim Biophys Acta (1977) 1.47
Phagosome dynamics and function. Bioessays (2000) 1.47
In vivo and in vitro binding of IgA to the plasma membrane of hepatocytes. Scand J Immunol (1978) 1.47
Mass isolation and culture of rat kupffer cells. J Exp Med (1975) 1.47
Management and outcomes of haemorrhage after pancreatogastrostomy versus pancreatojejunostomy. Br J Surg (2011) 1.46
Detection and characterization of norovirus outbreaks in Germany: application of a one-tube RT-PCR using a fluorogenic real-time detection system. J Med Virol (2004) 1.44
Diagnostic accuracy of forceps biopsy versus polypectomy for gastric polyps: a prospective multicentre study. Gut (2002) 1.43
Increase in norovirus activity reported in Europe. Euro Surveill (2006) 1.41
Bell's palsy - the effect of prednisolone and/or valaciclovir versus placebo in relation to baseline severity in a randomised controlled trial. Clin Otolaryngol (2012) 1.40
Pancreatic acinar cell carcinoma. An analysis of cell lineage markers, p53 expression, and Ki-ras mutation. Am J Pathol (1993) 1.39
[Inadvertent intravenous infusion of 380 mg ropivacaine]. Anaesthesist (2004) 1.38
Disposable-sheath, flexible gastroscope system versus standard gastroscopes: a prospective, randomized trial. Gastrointest Endosc (1999) 1.38
Radiotherapy alone or radiochemotherapy with platin derivatives following transurethral resection of the bladder. Organ preservation and survival after treatment of bladder cancer. Strahlenther Onkol (1998) 1.38
[Diagnosis of chronic hepatitis]. Dtsch Med Wochenschr (1997) 1.38
Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways. Infect Immun (2006) 1.38
Genetic diversity and recombination of murine noroviruses in immunocompromised mice. Arch Virol (2007) 1.37
De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroenterology (2000) 1.37
Immunoglobulin levels during childhood, with special regard to IgE. Acta Paediatr Scand (1969) 1.36
Distribution of lysosomal enzymes between parenchymal and Kupffer cells of rat liver. Biochim Biophys Acta (1973) 1.36
Demonstration of binding sites for IgG Fc and the third complement component (C3) on isolated hepatocytes. J Immunol (1976) 1.36
Isolation and characterization of early endosomes, late endosomes and terminal lysosomes: their role in protein degradation. J Cell Sci (1996) 1.35
Significance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastases. Eye (Lond) (2007) 1.35
Anterior chamber depth and complications during cataract surgery in eyes with pseudoexfoliation syndrome. Am J Ophthalmol (2000) 1.34
Fluid endocytosis in isolated rat parenchymal and non-parenchymal liver cells. Exp Cell Res (1980) 1.33
The effects of colchicine and cytochalasin B on uptake and degradation of asialo-glycoproteins in isolated rat hepatocytes. Exp Cell Res (1979) 1.32
Topogenesis and sorting of synaptophysin: synthesis of a synaptic vesicle protein from a gene transfected into nonneuroendocrine cells. Cell (1989) 1.32
Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut (2001) 1.32
In vitro fusion of phagosomes with different endocytic organelles from J774 macrophages. J Biol Chem (1998) 1.31
Clearance of acetyl low density lipoprotein by rat liver endothelial cells. Implications for hepatic cholesterol metabolism. J Biol Chem (1984) 1.31
Hepatic retinol metabolism. Distribution of retinoids, enzymes, and binding proteins in isolated rat liver cells. J Biol Chem (1985) 1.30
Distribution of lysosomal enzymes in different types of rat liver cells. Exp Cell Res (1976) 1.30
Adjuvant vs. neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO-94. Colorectal Dis (2003) 1.30
A functional toll-like receptor 8 variant is associated with HIV disease restriction. J Infect Dis (2008) 1.29